Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angeles Clinic and Research Institute
Maintenance biotherapy regimen slows metastatic melanoma progression
June 15th, 2005
Adding a novel maintenance biotherapy regimen to biochemotherapy protocols may significantly improve time-to-disease progression and overall survival in metastatic melanoma patients, according to new data presented at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO). "Because higher response rates have not translated to improved survival in multi-center randomized trials of biochemotherapy in metastatic melanoma, we wanted to see if we could repeat single-institution pilot data that suggested improved survival for patients receiving maintenance biotherapy following induction biochemotherapy," said lead study investigator Steven O'Day, MD,...
Source: Physician Law Weekly (2005-06-15)
|
